Abstract
In Australia death rates from cervical cancer have decreased by a factor of two over the past 50 years, presumably as a result of screening. This improvement has not been shared by all Australians, with Aboriginal women having 6–7 times the incidence and mortality rates of all Australian women, a result similar to native Americans [1]. Further, the age-specific mortality rate increases rapidly with age, and approaches the incidence rate. Thus in Australia there are groups with poor prognoses that warrant improved treatment modalities. In the third world cervical cancer often presents at an advanced stage. Such bulky tumours are resistant to photon irradiation as a result of extensive hypoxia. As a consequence, cervical cancer has poor survival and poor local control rates.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Jeffs P. (1995) Cervical Cancer in Australia, Australian Institute of Health and Welfare Cancer Series No 3
Hisao I, Kutuki S, Nishiguchi I et al. (1994) Radiotherapy for cervical cancer with high dose rate brachytherapy — correlation between tumour size, dose and failure, Radiotherapy and Oncology 31, 240–247
Maruyama Y, Van Nagell J R, Yoneda J, Donaldson E, Beach J L, Martin A, Kryscio R, Hansen M, Feola J M and Parker C. (1985) Neutron brachytherapy is better than conventional therapy in advanced cervical cancer, The Lancet May 18, 1120–1122
Maruyama Y, Van Nagell J R, Yoneda J, Donaldson E, Gallion H, Powell D and Kryscio R. (1991) A review of californium-252 neutron brachytherapy for cervical cancer, Cancer Sept 15, 1189–1197
Maruyama Y, Van Nagell J R, Yoneda J, Donaldson E, Gallion H, Rowley K, Kryscio R and Beach J L. (1987) Phase 1-2 clinical trial of Californium-252 treatment of stage 1B carcinoma of the cervix, Cancer 59:1500–1505
Californium-252 brachytherapy and fast neutron beam therapy, Ed: Y Maruyama, J L Beach, J M Feola, Nuclear Science Applications B, 2:3 1986
This workshop
Yanch J C, Zamenhof R G, Wierzbicki J and Maruyama Y, Comparison of dose distributions with B-10 augmentation near linear sources of Cf-252 obtained by Monte Carlo simulation and by experimental measurement. (1992) in B J Allen et al (eds), Progress in Neutron Capture Therapy for Cancer, 191–194
Yanch J Cand Zamenhof R G. (1992) Dosimetry of Cf-252 sources for neutron radiotherapy with and without augmentation by boron neutron capture therapy, Radiat Res 131:249–256
Krishnaswamy V. (1971) Calculation of the dose distribution about 252Cf needles in tissue, Radiology 98: 155–160
Bohm R, Nikodemova D, Fulop M and Pinak M. (1996) Monte Carlo simulation of 252Cf dose distribution brachytherapy, Med Phys 23: 5, 707–712
J F Briesmeister, MCNP-a general Monte Carlo code for neutron and photon transport, LA7396-M Rev 2, Los Alamos Laboratory, Los Alamos NM 1986
ICRU Report 46. Photon, Electron, Proton and Neutron Interaction for Body Tissues. 1992
ICRP23 Report of the task group on Reference Man 1975
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Ralston, A., Allen, B.J. (1997). CF-252 Brachytherapy in Cervical Cancer: Monte Carlo Studies of the Effect of Tissue Heterogeneity. In: Wierzbicki, J.G. (eds) Californium-252 Isotope for 21st Century Radiotherapy. NATO ASI Series, vol 29. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5766-7_22
Download citation
DOI: https://doi.org/10.1007/978-94-011-5766-7_22
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6433-0
Online ISBN: 978-94-011-5766-7
eBook Packages: Springer Book Archive